Literature DB >> 19679881

The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies.

Guergana Tchakarska, Anne Le Lan-Leguen, Lucile Roth, Brigitte Sola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19679881      PMCID： PMC2791925          DOI： 10.3324/haematol.2009.011460

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

Review 1.  Regulation and function of cyclin D2 in B lymphocyte subsets.

Authors:  Thomas C Chiles
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

Review 2.  Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.

Authors:  Christian Bogner; Christian Peschel; Thomas Decker
Journal:  Leuk Lymphoma       Date:  2006-02

3.  Genetic replacement of cyclin D1 function in mouse development by cyclin D2.

Authors:  Bradley C Carthon; Carola A Neumann; Manjusri Das; Basil Pawlyk; Tiansen Li; Yan Geng; Piotr Sicinski
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

4.  Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.

Authors:  M Klier; N Anastasov; A Hermann; T Meindl; D Angermeier; M Raffeld; F Fend; L Quintanilla-Martinez
Journal:  Leukemia       Date:  2008-08-07       Impact factor: 11.528

Review 5.  Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Authors:  K Podar; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

6.  Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.

Authors:  Rodger E Tiedemann; Xinliang Mao; Chang-Xin Shi; Yuan Xiao Zhu; Stephen E Palmer; Michael Sebag; Ron Marler; Marta Chesi; Rafael Fonseca; P Leif Bergsagel; Aaron D Schimmer; A Keith Stewart
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808
  6 in total
  6 in total

1.  Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.

Authors:  Young Shin Cho; Hayley Angove; Christopher Brain; Christine Hiu-Tung Chen; Hong Cheng; Robert Cheng; Rajiv Chopra; Kristy Chung; Miles Congreve; Claudio Dagostin; Deborah J Davis; Ruth Feltell; John Giraldes; Steven D Hiscock; Sunkyu Kim; Steven Kovats; Bharat Lagu; Kim Lewry; Alice Loo; Yipin Lu; Michael Luzzio; Wiesia Maniara; Rachel McMenamin; Paul N Mortenson; Rajdeep Benning; Marc O'Reilly; David C Rees; Junqing Shen; Troy Smith; Yaping Wang; Glyn Williams; Alison J-A Woolford; Wojciech Wrona; Mei Xu; Fan Yang; Steven Howard
Journal:  ACS Med Chem Lett       Date:  2012-05-17       Impact factor: 4.345

2.  Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.

Authors:  Shiri Weinstein; Itai A Toker; Rafi Emmanuel; Srinivas Ramishetti; Inbal Hazan-Halevy; Daniel Rosenblum; Meir Goldsmith; Avigdor Abraham; Ohad Benjamini; Osnat Bairey; Pia Raanani; Arnon Nagler; Judy Lieberman; Dan Peer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-23       Impact factor: 11.205

Review 3.  Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.

Authors:  Bijal D Shah; Peter Martin; Eduardo M Sotomayor
Journal:  Cancer Control       Date:  2012-07       Impact factor: 3.302

4.  Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.

Authors:  Leonardo Mirandola; Yuefei Yu; Kitty Chui; Marjorie R Jenkins; Everardo Cobos; Constance M John; Maurizio Chiriva-Internati
Journal:  PLoS One       Date:  2011-07-13       Impact factor: 3.240

5.  Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway.

Authors:  Sophie Bustany; Julie Cahu; Philippe Guardiola; Brigitte Sola
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

6.  RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma.

Authors:  Shiri Weinstein; Rafi Emmanuel; Ashley M Jacobi; Avigdor Abraham; Mark A Behlke; Andrew G Sprague; Tatiana I Novobrantseva; Arnon Nagler; Dan Peer
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.